Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements.'
The dosage schedule is available in the summary of product characteristics for durvalumab.
The list price is £2,466 per 500‑mg vial (excluding VAT; BNF online, accessed July 2024). The cost of a course of perioperative treatment of durvalumab is approximately £69,779.
The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence.